Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of Acinetobacter baumannii Mediated by the pmrAB Two-Component Regulatory System
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Colistin resistance is rare in Acinetobacter baumannii , and little is known about its mechanism. We investigated the role of PmrCAB in this trait, using (i) resistant and susceptible clinical strains, (ii) laboratory-selected mutants of the type strain ATCC 19606 and of the clinical isolate ABRIM, and (iii) a susceptible/resistant pair of isogenic clinical isolates, Ab15/133 and Ab15/132, isolated from the same patient. pmrAB sequences in all the colistin-susceptible isolates were identical to reference sequences, whereas resistant clinical isolates harbored one or two amino acid replacements variously located in PmrB. Single substitutions in PmrB were also found in resistant mutants of strains ATCC 19606 and ABRIM and in the resistant clinical isolate Ab15/132. No mutations in PmrA or PmrC were found. Reverse transcriptase (RT)-PCR identified increased expression of pmrA (4- to 13-fold), pmrB (2- to 7-fold), and pmrC (1- to 3-fold) in resistant versus susceptible organisms. Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry showed the addition of phosphoethanolamine to the hepta-acylated form of lipid A in the resistant variants and in strain ATCC 19606 grown under low-Mg 2+ induction conditions. pmrB gene knockout mutants of the colistin-resistant ATCC 19606 derivative showed >100-fold increased susceptibility to colistin and 5-fold decreased expression of pmrC ; they also lacked the addition of phosphoethanolamine to lipid A. We conclude that the development of a moderate level of colistin resistance in A. baumannii requires distinct genetic events, including (i) at least one point mutation in pmrB , (ii) upregulation of pmrAB , and (iii) expression of pmrC , which lead to addition of phosphoethanolamine to lipid A.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tenover, F. C., Arbeit, R. D., Goering, R. V., Mickelsen, P. A., Murray, B. E., Persing, D. H., & Swaminathan, B. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.9.2233-2239.1995 · Cited by 8,204
Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features
Bergogne-Bérézin, E., & Towner, K. J. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.2.148 · Cited by 1,711
Hancock, R. E. (1997) · The Lancet · doi:10.1016/s0140-6736(97)80051-7 · Cited by 1,096
Moffatt, J. H., Harper, M., Harrison, P., Hale, J. D. F., Vinogradov, E., Seemann, T., Henry, R., Crane, B., St. Michael, F., Cox, A. D., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00834-10 · Cited by 812
BSAC standardized disc susceptibility testing method (version 7)
Andrews, J. M., & Testing, F. T. B. W. P. O. S. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn194 · Cited by 734
Gunn, J. S., Lim, K. B., Krueger, J., Kim, K., Guo, L., Hackett, M., & Miller, S. I. (1998) · Molecular Microbiology · doi:10.1046/j.1365-2958.1998.00757.x · Cited by 655
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria
Li, J., Nation, R. L., Milne, R. W., Turnidge, J. D., & Coulthard, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.10.001 · Cited by 571
Regulation of Lipid A Modifications by Salmonella typhimurium Virulence Genes phoP-phoQ
Guo, L., Lim, K. B., Gunn, J. S., Bainbridge, B., Darveau, R. P., Hackett, M., & Miller, S. I. (1997) · Science · doi:10.1126/science.276.5310.250 · Cited by 559
Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii
Li, J., Rayner, C. R., Nation, R. L., Owen, R. J., Spelman, D., Tan, K. E., & Liolios, L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00103-06 · Cited by 548
Specific Lipopolysaccharide Found in Cystic Fibrosis Airway Pseudomonas aeruginosa
Ernst, R. K., Yi, E. C., Guo, L., Lim, K. B., Burns, J. L., Hackett, M., & Miller, S. I. (1999) · Science · doi:10.1126/science.286.5444.1561 · Cited by 484
Cited by
Molecular mechanisms of antibiotic resistance
Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. V. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3380 · Cited by 4,092
Poirel, L., Jayol, A., & Nordmann, P. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00064-16 · Cited by 1,447
Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria
Olaitan, A. O., Morand, S., & Rolain, J.-M. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00643 · Cited by 1,395
Beceiro, A., Tomás, M., & Bou, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00059-12 · Cited by 1,070
Self-citationUncovering the mechanisms of Acinetobacter baumannii virulence
Harding, C. M., Hennon, S. W., & Feldman, M. F. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.148 · Cited by 1,026
Lee, C.-R., Lee, J. H., Park, M., Park, K. S., Bae, I. K., Kim, Y. B., Cha, C.-J., Jeong, B. C., & Lee, S. H. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00055 · Cited by 1,016
Potron, A., Poirel, L., & Nordmann, P. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.03.001 · Cited by 688
Combination approaches to combat multidrug-resistant bacteria
Worthington, R. J., & Melander, C. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.12.006 · Cited by 625
Colistin: an update on the antibiotic of the 21st century
Biswas, S., Brunel, J.-M., Dubus, J.-C., Reynaud-Gaubert, M., & Rolain, J.-M. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.78 · Cited by 581
Permeability Barrier of Gram-Negative Cell Envelopes and Approaches To Bypass It
Zgurskaya, H. I., López, C. A., & Gnanakaran, S. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00097 · Cited by 580
Cai, Y., Chai, D., Wang, R., Liang, B., & Bai, N. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks084 · Cited by 557
Bacterial stress responses as determinants of antimicrobial resistance
Poole, K. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks196 · Cited by 519
Towards Understanding MCR-like Colistin Resistance
Sun, J., Zhang, H., Liu, Y.-H., & Feng, Y. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.02.006 · Cited by 446
Current Epidemiology and Growing Resistance of Gram-Negative Pathogens
Livermore, D. M. (2012) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2012.27.2.128 · Cited by 417
Self-citationColistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
Qureshi, Z. A., Hittle, L. E., O'Hara, J. A., Rivera, J. I., Syed, A., Shields, R. K., Pasculle, A. W., Ernst, R. K., & Doi, Y. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ048 · Cited by 395
The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace
Roca, I., Espinal, P., Vila-Farrés, X., & Vila, J. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00148 · Cited by 363
Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside
Lin, M.-F. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i12.787 · Cited by 357
Tackling Threats and Future Problems of Multidrug-Resistant Bacteria
Medina, E., & Pieper, D. H. (2016) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2016_492 · Cited by 356
Acinetobacter baumannii: Evolution of Antimicrobial Resistance—Treatment Options
Murray, G., Peleg, A., & Doi, Y. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1398388 · Cited by 316
Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?
Nation, R. L., Velkov, T., & Li, J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu213 · Cited by 310
Hrabák, J., Chudáčková, E., & Walková, R. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-12 · Cited by 304
Acinetobacter baumannii Resistance: A Real Challenge for Clinicians
Vázquez-López, R., Solano-Gálvez, S. G., Juárez Vignon-Whaley, J. J., Abello Vaamonde, J. A., Padró Alonzo, L. A., Rivera Reséndiz, A., Muleiro Álvarez, M., Vega López, E. N., Franyuti-Kelly, G., Álvarez-Hernández, D. A., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9040205 · Cited by 296
Kidd, T. J., Mills, G., Sá‐Pessoa, J., Dumigan, A., Frank, C. G., Insua, J. L., Ingram, R., Hobley, L., & Bengoechea, J. A. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607336 · Cited by 163
“…Pseudomonas) also synthesise lipid A species possessing a hydroxyl group on a secondary acyl chain (Kulshin et al , 1991; Zahringer et al , 1995; Gibbons et al , 2000; Beceiro et al , 2011) could indicate that this lipid A modification is a conserved mechanism to counteract antimicrobial peptides.”
Self-citationPharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new?
Bergen, P. J., Landersdorfer, C. B., Zhang, J., Zhao, M., Lee, H. J., Nation, R. L., & Li, J. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.07.010 · Cited by 162
“…and/or phosphoethanolamine, reduce the net negative charge of lipid A, thereby increasing resistance to polymyxins (Adams et al., 2009; Beceiro et al., 2011; Clements et al., 2007; Fernandez et al., 2010; Helander et al., 1994, 1996; Moskowitz et al., 2004 ; Perez and Groisman, 2007).”
BackgroundLowings, M., Ehlers, M. M., Dreyer, A. W., & Kock, M. M. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1246-8 · Cited by 68
“baumannii treatment [25–28].”
Carballo-Pacheco, M., Nicholson, M. D., Lilja, E. E., Allen, R. J., & Waclaw, B. (2020) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1007930 · Cited by 18
“Examples are quinolones that lock the enzyme DNA gyrase onto the DNA and prevent DNA replication [37], and polymixins that bind to lipids in the outer membrane which causes membrane perforation [38, 39].”
Metadata
- Authors
- Beceiro, A., Llobet, E., Aranda, J., Bengoechea, J. A., Doumith, M., Hornsey, M., Dhanji, H., Chart, H., Bou, G., Livermore, D. M., & Woodford, N.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-07
- Volume
- 55
- Issue
- 7
- Pages
- 3370-3379
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2147706925
- Cited by
- 379
- References
- 43
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.